Malartan Hct (Valsartan, Hydrochlorothiazide)

Malartan Hct, a fixed‑dose antihypertensive combination, is used to manage conditions related to high blood pressure.

• Hypertension: lowers systolic and diastolic blood pressure, helping achieve target levels.
• Hypertensive‑related edema: promotes diuresis to reduce fluid accumulation associated with elevated pressure.
• Cardiovascular risk reduction in hypertensive patients: contributes to decreased risk of stroke and myocardial infarction when used as part of comprehensive therapy.

• Valsartan selectively blocks angiotensin II type 1 (AT1) receptors on vascular smooth muscle and adrenal tissue, preventing vasoconstriction and aldosterone release. Hydrochlorothiazide acts on the distal convoluted tubule, inhibiting NaCl reabsorption, which increases urinary sodium and water excretion, lowering plasma volume. The overall combined actions produce significant additive blood pressure reduction, effectively decreasing peripheral resistance and intravascular volume.

Common and serious adverse reactions have been reported with the Valsartan/Hydrochlorothiazide combination.

Common Side Effects

• Dizziness: light‑headed sensation, especially on standing.
• Headache: mild to moderate pain.
• Increased urination: due to the diuretic component.
• Fatigue: general tiredness.

Serious or Rare Side Effects

• Hyperkalemia: elevated potassium that may affect cardiac rhythm.
• Acute kidney injury: sudden decline in renal function.
• Severe hypotension: marked drop in blood pressure causing faintness.

When prescribing Malartan Hct, clinicians should consider several precautionary measures to ensure safe use.

• Renal function: assess baseline kidney function and monitor periodically.
• Electrolytes: check serum potassium and sodium before initiation and during therapy.
• Concomitant diuretics: avoid excessive diuresis when combined with other diuretics.
• Pregnancy: avoid use unless clearly needed, as safety data are limited.
• Elderly patients: start at lower dose and monitor for orthostatic hypotension.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Malartan Hct may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• ACE inhibitors or other ARBs: risk of additive hyperkalemia and renal impairment.
• Lithium: increased lithium levels leading to toxicity.
• NSAIDs: may reduce antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely)

• Potassium‑sparing diuretics or supplements: monitor serum potassium.
• Antidiabetic agents: may enhance hypoglycemic effect.
• Cyclosporine or tacrolimus: may increase serum concentrations of Valsartan.